Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two-drug regimen in SWORD-1/-2 phase 3 studies.

Rashmi Mehta,Chakradhar V Lagishetty,Konstantinos Angelis,Alicia Aylott,Lesley Kahl,Libby Blair,Jessica Matthews,Brian Wynne,Herta Crauwels,Mark Underwood,Kimberly K Adkison

British journal of clinical pharmacology（2023）

引用 0|浏览6

暂无评分

摘要

No clinically relevant relationship between DTG or RPV exposures and virologic or safety response was observed, confirming the DTG + RPV switch for participants as a safe and effective treatment.

查看译文

关键词

HIV/AIDS,pharmacokinetic-pharmacodynamic,systemic pharmacology

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要